Summary of the interim report
The “Company” or “Xintela” refers to
Third quarter 2023 for the group
Income amounted to TSEK 0 (0).
Loss before tax totalled TSEK 11,953 (loss: 14,456).
Loss per share was
First nine month 2023 for the group
Income amounted to TSEK 0 (0).
Loss before and tax totalled TSEK 46,192 (loss: 49,781).
Loss per share was
Third quarter 2023 for the parent company
Income amounted to TSEK 0 (0).
Loss before tax totalled TSEK 8,916 (loss: 9,197).
Loss per share was
First nine month 2023 for the parent company
Income amounted to TSEK 0 (0).
Loss before tax totalled TSEK 30,469 (loss: 31,786).
Loss per share was
At
Significant events in the third quarter of 2023
Significant events after the end of the period
Xintela’s stem cell product, XSTEM, has been assessed as safe at all dose levels in knee osteoarthritis clinical study. (
The complete report is available for download below and on the company’s website www.xintela.se/en/investors#reports.
© Modular Finance, source